Loading
NASDAQHealthcareMedical - Devices
Latest quote
$0.77
−$0.02 · -2.53%
Based in China, Baird Medical Investment Holdings Limited and its associated entities specialize in engineering and commercializing microwave ablation medical apparatus. These sophisticated instruments are employed in the minimally invasive management of a diverse array of benign and malignant tumors, notably targeting thyroid nodules, hepatic carcinomas, pulmonary cancers, and mammary lesions. The organization was established in 2012, with its corporate headquarters situated in Guangzhou, China.
Previous close
$0.77
−$0.02 · -2.53%
After-hours
$0.7998
+$0.0298 · +3.87%
Oct 9, 5:53 PM ET
Regular session · ET · Market data may be delayed.
Based in China, Baird Medical Investment Holdings Limited and its associated entities specialize in engineering and commercializing microwave ablation medical apparatus. These sophisticated instruments are employed in the minimally invasive management of a diverse array of benign and malignant tumors, notably targeting thyroid nodules, hepatic carcinomas, pulmonary cancers, and mammary lesions. The organization was established in 2012, with its corporate headquarters situated in Guangzhou, China.
Day range
Current $0.77
52-week range
Current $0.77
Regular session · ET · Market data may be delayed.
GoAI Score
Hold
Valuation
65
Undervalued
Sentiment
55
Mixed
Risk
66
High Risk
Momentum
18
Strong Down
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Based in China, Baird Medical Investment Holdings Limited and its associated entities specialize in engineering and commercializing microwave ablation medical apparatus. These sophisticated instruments are employed in the minimally invasive management of a diverse array of benign and malignant tumors, notably targeting thyroid nodules, hepatic carcinomas, pulmonary cancers, and mammary lesions. The organization was established in 2012, with its corporate headquarters situated in Guangzhou, China.
Day range
Current $0.77
52-week range
Current $0.77
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 22.54M USD | 37.04M USD | 31.46M USD | 35.09M USD | 27.72M USD |
| Cost of goods sold | 3.65M USD | 4.38M USD | 4.23M USD | 7.05M USD | 4.54M USD |
| Gross profit | 18.88M USD | 32.65M USD | 27.23M USD | 28.04M USD | 23.18M USD |
| Research and development | 20.13M USD | 6.17M USD | 4.27M USD | 3.86M USD | 1.04M USD |
| Selling, general, and administrative | 24.38M USD | 9.96M USD | 11.09M USD | 10.55M USD | 10.22M USD |
| Operating expenses | 44.42M USD | 17.34M USD | 15.37M USD | 13.03M USD | 9.76M USD |
| Interest income | — | 393 USD | — | 8.55K USD | 2.33K USD |
| Interest expense | 737.37K USD | 576.75K USD | 284.27K USD | 299.27K USD | 153.92K USD |
| Depreciation and amortization | 1.1M USD | 1.51M USD | 1.38M USD | 1.47M USD | 1.4M USD |
| Operating income | −25.54M USD | 15.32M USD | 11.86M USD | 13.63M USD | 11.92M USD |
| Net income | −27.28M USD | 12.45M USD | 10.55M USD | 12.57M USD | 11.68M USD |
Company facts updated Oct 10, 2026.
Reported history and fiscal-year consensus
Reported history and fiscal-year consensus
AI-generated and delayed market data for informational and educational purposes only. Not investment advice.
